lumacyte label-free single cell analysis and sorting products and services
TRANSCRIPT
LumaCyte Technology & Applications:
The Benefits of Label-Free Single Cell Analysis
and Sorting
Label-based Analysis
o Label-based analysis is used extensively in flow
cytometry and microscopy
o Labels include antibodies and genetic markers
(e.g. green fluorescent protein)
o Label-based analysis is:
• Widely used
• Highly specific
• Commoditized
o However, it is not without problems and limitations
Limits of Label-based Analysis
o Inaccurate: Analysis skewed by presupposition
of labels needed to identify target cells.
o Incomplete: Cannot detect cells expressing
unknown or unexpressed surface target
proteins or antigens (false negatives). Antibody
non-specific binding can lead to false positives.
o Biased: Labels can affect cells causing
biochemical changes thereby biasing results.
o Inefficient: Resource-intensive activities
increase errors, consume time and capital.
RadianceTM
Lighting the Way…
RadianceTM is a microfluidic
and optical instrument for
label-free cell analysis and
sorting.
RadianceTM
Fundamental Technology
o Initiates and measures
optical force on single
cells
o Precisely characterizes
intrinsic cellular properties:
• Shape, Morphology
• Biochemistry
• Deformability
RadianceTM
o Microfluidic environment
precisely controls cells, enabling
single cell analysis and sorting
o High resolution imaging and
video capture of each cell
o Cells are viable after sorting for
further analysis
o Small volumes can be used to
conserve precious samples
Features
Deformability, Optical Force and Biology
o Deformability is measured to gauge cytoskeletal changes
due to disease, cell state or pharmaceutical action
o Optical force is a complex, sensitive quantity that reflects
a variety of phenotypic changes within a cell
Factors Affecting Optical Force
RadianceTM : Who Benefits?
Small, mid-size and global biopharmas that want to
control costs while simultaneously increasing the
reach and accuracy of their research.
RadianceTM Key Applications
o Phenotypic Drug Discovery
(PDD)
o Vaccine Development – rapid
viral titering and infectivity
studies
o Cell Clearance – apoptosis,
macrophages
o Cancer Biology – solid and
circulating tumor cells
0
0.05
0.1
0.15
0.2
0.25
500 550 600 650 700 750 800 850 900 950 1000 1050 1100 1150 1200 1250 1300 1350
Fre
qu
en
cy
Average Velocity (mm/sec)
Control Day 2
MOI 1 Day 2
MOI 5 Day 2
975
Adenovirus Infection in HEK 293 Cells
Infected cells can be rapidly
identified by their low velocity
o Traditional methods to detect virus can take 5 – 10+ days o Infection of mammalian cells can be seen in 2 days or
less using RadianceTM
o The percentage of low velocity cells measured correlates with the viral titer of the sample
Apoptosis in adenocarcinoma cells (A549)
staurosporine
Induction of apoptosis changes cell morphology, biochemical composition and optical force
HCC2429 tumor cell line
Focal point of laser beam Deformability
Deformability in Lung Cancer Cells
Entry point Native cell shape
Time lapse images showing cell deformability measured using RadianceTM
Cancer Drug Candidate Testing
Selumetinib: an oral small-molecule MEK inhibitor
Tested on adenocarcinoma cells (A549)
0
0.02
0.04
0.06
0.08
0.1
0.12
125 175 225 275 325 375 425 475 525 575 625 675 725 775 825 875 925 975 10251075112511751225127513251375
Fre
qu
en
cy
Average Velocity (microns/sec)
Untreated
2 uM Selumetinib
20uM Selumetinib
700
750
800
850
900
950
1000
Untreated 2uM Sel 20uM Sel
Average velocity 93%
66%
20%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Untreated 2uM Sel 20uM Sel
Viability
o Cellular response to drug candidates can be quantified using optical force measurements
Cancer Drug Candidate Testing
Selumetinib: an oral small-molecule MEK inhibitor
Tested on adenocarcinoma cells (A549)
0
0.02
0.04
0.06
0.08
0.1
0.12
125 175 225 275 325 375 425 475 525 575 625 675 725 775 825 875 925 975 10251075112511751225127513251375
Fre
qu
en
cy
Average Velocity (microns/sec)
Untreated
2 uM Selumetinib
20uM Selumetinib
o Cellular changes can be measured using optical force, deformability, and imaging to better understand drug candidate action on cells
Lighting the Way….Learn More About LumaCyte
Sean Hart, Ph.D. President, Chief Executive Officer
Dr. Hart led the second group in the world
to research optical chromatography that
led to the invention of the technology used
in RadianceTM.
• PhD in Chemistry from Tufts University
• 4 patents issued / 4 patents pending
• 50+ journal articles
Thank you for your time and kind consideration.
Lumacyte.com
(888) 472-9295